Abstract：
Over the past 30 years the incorporation of monoclonal antibody (mAb) treatments into the management of hematologic malignancies has led to significant improvements in patient outcomes. The key limitation of mAb treatments is the necessity for target antigen presentation on major histocompatibility complex (MHC) and costimulatory molecules to elicit a cytotoxic immune response. With the advent of bispecific antibodies (BsAbs), these limitations can be overcome through direct stimulation of cytotoxic T cells, thus limiting tumor cell evasion. BsAbs are rapidly being incorporated into treatment regimens for hematologic malignancies, and there are now seven FDA-approved treatments in this class, six of which have been approved in the past year. In this review we describe the function, complications, and clinical trial data available for CD3 BsAbs in the treatment of lymphoma, myeloma, and leukemia.
摘要：
在过去的30年中，将单克隆抗体（mAb）治疗纳入血液恶性肿瘤的治疗中已导致患者预后的显着改善。mAb治疗的关键限制是在主要组织相容性复合物(MHC)和共刺激分子上的靶抗原呈递以引发细胞毒性免疫应答的必要性。随着双特异性抗体（BsAbs）的出现，这些限制可以通过直接刺激细胞毒性T细胞来克服，从而限制了肿瘤细胞的逃避。BsAb正在迅速纳入血液系统恶性肿瘤的治疗方案，现在有七种FDA批准的治疗方法，其中六项在过去一年获得批准。在这篇综述中，我们描述了函数，并发症,以及CD3BsAb治疗淋巴瘤的临床试验数据，骨髓瘤,和白血病。
